<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03585153</url>
  </required_header>
  <id_info>
    <org_study_id>130883</org_study_id>
    <secondary_id>3-SRA-2019-759-M-B</secondary_id>
    <secondary_id>3-SRA-2015-102-M-B</secondary_id>
    <nct_id>NCT03585153</nct_id>
  </id_info>
  <brief_title>Multicenter Assessment of the Pancreas in Type 1 Diabetes</brief_title>
  <acronym>MAP-T1D</acronym>
  <official_title>Multicenter Assessment of the Pancreas in Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Texas at Austin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St Vincent's Institute of Medical Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Juvenile Diabetes Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall goal of this research is to develop and validate standard operating procedures&#xD;
      (SOP) to assess the human pancreas in individuals with type 1 diabetes (T1D) and other forms&#xD;
      of diabetes using advanced, quantitative magnetic resonance imaging (MRI) approaches.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This research applies magnetic resonance imaging (MRI) techniques to study the pancreas of&#xD;
      individuals with type 1 diabetes (T1D) and other forms of diabetes. Recent studies have&#xD;
      demonstrated reduced pancreatic volume is present within months of T1D diagnosis in children,&#xD;
      adolescents, and adults, and in non-diabetic individuals expressing islet autoantibodies that&#xD;
      portend the development of T1D. As the pancreatic beta cells constitute only 1-2% of the&#xD;
      pancreas, the degree of reduction in pancreas volume at disease onset suggests exocrine&#xD;
      involvement, challenging the established paradigm of T1D being solely a disease of the&#xD;
      endocrine pancreas. These unexpected findings raise fundamental questions that challenge our&#xD;
      understanding of T1D pathogenesis. These changes in pancreatic volume and size before and&#xD;
      soon after onset of T1D, as detected by MRI, appear to be a marker of the T1D pathogenic&#xD;
      disease process. There is an urgent need to determine whether similar observations can be&#xD;
      obtained at different centers using different MRI platforms. Discovery of unknown changes may&#xD;
      lead to new ways to treat disease. The MRI techniques may also be useful for following how&#xD;
      T1D is progressing in different people, determining whether new drugs are effective, and&#xD;
      ultimately detecting T1D in people earlier than currently possible.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">February 19, 2014</start_date>
  <completion_date type="Anticipated">June 2050</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Pancreas Volume Index</measure>
    <time_frame>Duration of subject's participation in the study</time_frame>
    <description>Size of the pancreas determined by longitudinal MRI, normalized to subject weight</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MRI of pancreas - Apparent Diffusion Coefficient</measure>
    <time_frame>Duration of subject's participation in the study</time_frame>
    <description>MRI texture of pancreas</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1D Genetic Risk Score</measure>
    <time_frame>Once, at study enrollment</time_frame>
    <description>Saliva will be collected and used to make DNA to determine a T1D genetic risk score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1D Autoantibodies</measure>
    <time_frame>Once, at study enrollment</time_frame>
    <description>Control subjects who enroll will be asked to have their blood drawn to determine their T1D autoantibody status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary C-peptide/creatinine</measure>
    <time_frame>Once for controls, at study enrollment; Possibly at each visit for T1D</time_frame>
    <description>Urine may be collected on all participants to assess urinary C-peptide/creatinine ratio</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>T1D</arm_group_label>
    <description>Individuals with type 1 diabetes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Individuals without type 1 diabetes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aab+</arm_group_label>
    <description>Individuals without type 1 diabetes who possess 2+ type 1 diabetes-related autoantibodies</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MODY</arm_group_label>
    <description>Individuals with monogenic diabetes, or maturity-onset diabetes of the young (MODY)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Non-contrast magnetic resonance imaging</intervention_name>
    <description>subjects lie in an MRI machine (non-contrast) for 30 minutes while we take pictures of their pancreas</description>
    <arm_group_label>Aab+</arm_group_label>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>MODY</arm_group_label>
    <arm_group_label>T1D</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood; mouth saliva swab; urine&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Individuals with diabetes for this study may be referred by any pediatric or adult&#xD;
        endocrinologists. Healthy controls are recruited via a passive recruitment process. A small&#xD;
        subset of controls will travel to multiple study centers to have an MRI. In this study, the&#xD;
        MRI scan will be used for research purposes only. However, if we see something that is not&#xD;
        normal, the participant will be told and asked to consult his or her doctor.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects at least 8 years of age&#xD;
&#xD;
          -  Subjects with T1D must be imaged within 100 days of their date of diagnosis&#xD;
&#xD;
          -  Subjects must be able to read and provide assent/informed written consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with pancreatitis, cystic fibrosis, pancreatic adenocarcinoma, or&#xD;
             neuroendocrine tumors&#xD;
&#xD;
          -  Subjects who have any type of bioimplant activated by mechanical, electronic, or&#xD;
             magnetic means because such devices may be displaced or malfunction&#xD;
&#xD;
          -  Subjects who have any type of ferromagnetic bioimplant that could potentially be&#xD;
             displaced&#xD;
&#xD;
          -  Subjects who are pregnant or breast-feeding. Urine pregnancy test will be performed on&#xD;
             women of child bearing potential who are not practicing appropriate contraception&#xD;
             measures or menstruating.&#xD;
&#xD;
          -  Subjects who exhibit significant anxiety and/or claustrophobia&#xD;
&#xD;
          -  Subjects incapable of giving assent/informed written consent&#xD;
&#xD;
          -  For controls: subjects who have first degree relatives with T1D&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alvin C. Powers, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado, Barbara Davis Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago, Kovler Diabetes Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas at Austin, Dell Medical School</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent's Institute of Medical Research</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Virostko J, Williams J, Hilmes M, Bowman C, Wright JJ, Du L, Kang H, Russell WE, Powers AC, Moore DJ. Pancreas Volume Declines During the First Year After Diagnosis of Type 1 Diabetes and Exhibits Altered Diffusion at Disease Onset. Diabetes Care. 2019 Feb;42(2):248-257. doi: 10.2337/dc18-1507. Epub 2018 Dec 14.</citation>
    <PMID>30552135</PMID>
  </results_reference>
  <results_reference>
    <citation>Williams JM, Hilmes MA, Archer B, Dulaney A, Du L, Kang H, Russell WE, Powers AC, Moore DJ, Virostko J. Repeatability and Reproducibility of Pancreas Volume Measurements Using MRI. Sci Rep. 2020 Mar 16;10(1):4767. doi: 10.1038/s41598-020-61759-9.</citation>
    <PMID>32179809</PMID>
  </results_reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>June 18, 2018</study_first_submitted>
  <study_first_submitted_qc>June 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2018</study_first_posted>
  <last_update_submitted>April 18, 2021</last_update_submitted>
  <last_update_submitted_qc>April 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>Al Powers</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

